Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

1.

Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer.

Coen JJ, Paly JJ, Niemierko A, Kaufman DS, Heney NM, Spiegel DY, Efstathiou JA, Zietman AL, Shipley WU.

Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):311-6. doi: 10.1016/j.ijrobp.2013.01.020. Epub 2013 Mar 6.

PMID:
23474117
[PubMed - indexed for MEDLINE]
2.

Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.

Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, Coen JJ, Skowronski RY, Paly JJ, McGovern FJ, Zietman AL.

Eur Urol. 2012 Apr;61(4):705-11. doi: 10.1016/j.eururo.2011.11.010. Epub 2011 Nov 12.

PMID:
22101114
[PubMed - indexed for MEDLINE]
3.
4.

The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?

Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM, Kaufman DS, Zietman AL.

BJU Int. 2009 Jul;104(2):179-83. doi: 10.1111/j.1464-410X.2008.08299.x. Epub 2008 Dec 23.

PMID:
19154448
[PubMed - indexed for MEDLINE]
5.

A pretreatment nomogram predicting recurrence- and progression-free survival for nonmuscle invasive bladder cancer in Japanese patients.

Yamada T, Tsuchiya K, Kato S, Kamei S, Taniguchi M, Takeuchi T, Yamamoto N, Ehara H, Deguchi T.

Int J Clin Oncol. 2010 Jun;15(3):271-9. doi: 10.1007/s10147-010-0049-6. Epub 2010 Mar 2.

PMID:
20195678
[PubMed - indexed for MEDLINE]
6.

Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.

Zietman AL, Grocela J, Zehr E, Kaufman DS, Young RH, Althausen AF, Heney NM, Shipley WU.

Urology. 2001 Sep;58(3):380-5.

PMID:
11549485
[PubMed - indexed for MEDLINE]
7.

Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience.

Tunio MA, Hashmi A, Qayyum A, Mohsin R, Zaeem A.

Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e457-62. doi: 10.1016/j.ijrobp.2011.05.051. Epub 2011 Sep 22.

PMID:
21945107
[PubMed - indexed for MEDLINE]
9.

Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.

International Bladder Cancer Nomogram Consortium, Bochner BH, Kattan MW, Vora KC.

J Clin Oncol. 2006 Aug 20;24(24):3967-72. Epub 2006 Jul 24. Erratum in: J Clin Oncol. 2007 Apr 10;25(11):1457.

PMID:
16864855
[PubMed - indexed for MEDLINE]
10.

Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial.

Azria D, Riou O, Rebillard X, Thezenas S, Thuret R, Fenoglietto P, Pouessel D, Culine S.

Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):853-9. doi: 10.1016/j.ijrobp.2013.11.016. Epub 2013 Dec 21.

PMID:
24368064
[PubMed - indexed for MEDLINE]
11.

Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer.

Tsai HK, Katz MS, Coen JJ, Zietman AL, Kaufman DS, Shipley WU.

Urology. 2006 Dec;68(6):1188-92. Epub 2006 Dec 4.

PMID:
17141846
[PubMed - indexed for MEDLINE]
12.

Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.

Koga F, Fujii Y, Masuda H, Numao N, Yokoyama M, Ishioka J, Saito K, Kawakami S, Kihara K.

BJU Int. 2012 Sep;110(6 Pt B):E203-8. doi: 10.1111/j.1464-410X.2011.10874.x. Epub 2012 Jan 30.

PMID:
22289431
[PubMed - indexed for MEDLINE]
13.

Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer.

Shipley WU, Kaufman DS, Zehr E, Heney NM, Lane SC, Thakral HK, Althausen AF, Zietman AL.

Urology. 2002 Jul;60(1):62-7; discussion 67-8.

PMID:
12100923
[PubMed - indexed for MEDLINE]
14.

Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.

May M, Helke C, Nitzke T, Vogler H, Hoschke B.

Urol Int. 2004;72(2):103-11.

PMID:
14963349
[PubMed - indexed for MEDLINE]
15.

Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.

Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, Sagalowsky AI, Schoenberg M, Lerner SP.

J Urol. 2006 Oct;176(4 Pt 1):1354-61; discussion 1361-2.

PMID:
16952631
[PubMed - indexed for MEDLINE]
16.

Bladder function preservation with brachytherapy, external beam radiation therapy, and limited surgery in bladder cancer patients: long-term results.

Aluwini S, van Rooij PH, Kirkels WJ, Boormans JL, Kolkman-Deurloo IK, Wijnmaalen A.

Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):611-7. doi: 10.1016/j.ijrobp.2013.11.227. Epub 2014 Jan 7.

PMID:
24411629
[PubMed - indexed for MEDLINE]
17.

Selective organ preservation in muscle-invasive bladder cancer: review of the literature.

Khosravi-Shahi P, Cabezón-Gutiérrez L.

Surg Oncol. 2012 Mar;21(1):e17-22. doi: 10.1016/j.suronc.2011.10.004. Epub 2011 Nov 16. Review.

PMID:
22088598
[PubMed - indexed for MEDLINE]
18.

Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy.

Kozak KR, Hamidi M, Manning M, Moody JS.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e197-204. doi: 10.1016/j.ijrobp.2011.12.038. Epub 2012 Mar 6.

PMID:
22401916
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Outcome of trimodality protocol for invasive bladder cancer patients at Karachi, Pakistan.

Tunio MA, Hashmi A, Qayyum A, Naimatullah N, Mohsin R, Sultan G.

J Pak Med Assoc. 2011 Sep;61(9):874-9.

PMID:
22360027
[PubMed - indexed for MEDLINE]
20.

Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.

Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, True L, Shipley W.

J Clin Oncol. 1996 Jan;14(1):119-26.

PMID:
8558186
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk